Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
XFOR Stock — X4 Pharmaceuticals Inc
X4 Pharmaceuticals Inc (XFOR)
Updated October 16, 2026.
XFOR is a Stock. Total return is -99.9% over the past 8.9 years, 338.6 points behind SPY at 238.7%.
X4 Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for rare immune system diseases. Its lead program, XOLREMDI, is an orally administered small-molecule drug candidate currently in phase 3 clinical trials for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, with licensing agreements in place for commercialization in China, Europe, and Australia. The company does not currently distribute income to shareholders.
XFOR dividend yield and income
Price as of 2026-10-16.
The payment date is 03/14/2019.
XFOR performance versus SPY
Price and return data through 2026-10-16.
Total return is -99.9% over the past 8.9 years, 338.6 points behind SPY at 238.7%. Over the past year its total return — price change plus distributions reinvested — is -12.8%. Its deepest 1-year drawdown was 47.5%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -26.2% | — |
| 3M | -32.4% | — |
| 6M | -37.4% | — |
| YTD | -35.2% | — |
| 1Y | -12.8% | — |
| 2Y CAGR | — | -59.80% |
| 3Y CAGR | — | -54.90% |
| 5Y CAGR | — | -56.00% |
| Since inception (8.9 years) | -99.9% | -53.80% |
XFOR key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 11/16/2017
- Distribution frequency
- None
- Last close
- $2.59 (as of 2026-10-16)
- Market cap
- $256,790,064
- Average volume
- 967582.0
- Payment date
- 03/14/2019
- Beta
- 0.461
- Payout ratio
- 0.0%
- P/E ratio
- 129.5
- EPS
- $0.02
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
XFOR risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 47.5%.
Who may consider XFOR — and who may not
It is a weaker fit for investors who need monthly cash flow (XFOR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on XFOR
Frequently asked questions
Does XFOR pay monthly?
No. XFOR does not currently distribute.
When does XFOR pay a dividend?
XFOR does not currently distribute. The payment date is 03/14/2019.
How has XFOR performed?
Total return is -99.9% over the past 8.9 years, 338.6 points behind SPY at 238.7%. Over the past year its total return — price change plus distributions reinvested — is -12.8%. Its deepest 1-year drawdown was 47.5%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.